Acute graft-versus-host disease (GVHD) occurs less frequently after umbilical cord blood transplantation (UCBT). More recent investigations include the use of two partially HLA matched UCB units, or 'double UCB graft', in an effort to meet the minimum cell dose requirement. The purpose of this analysis was to assess the relative risk of acute GVHD in 265 consecutive patients transplanted with UCB graft composed of one (n=80) or two (n=185) units. The incidence of grade III-IV acute GVHD was similar between cohorts.
Introduction
In general, acute graft-versus-host-disease (GVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). [1] [2] [3] [4] Risk factors for the development of acute GVHD have consistently included recipient age, CMV serostatus, donor hematopoietic stem cell (HSC) source, and HLA disparity.
Increasingly, umbilical cord blood (UCB) is chosen as an alternative to bone marrow or peripheral blood stem cells, especially for those without an HLA matched donor. [5] [6] [7] [8] [9] [10] [11] [12] [13] Despite one to two antigen disparities between the donor and host, acute GVHD occurs with lower frequency after UCB transplantation relative to that observed after HLA matched marrow from unrelated donors. [14] [15] [16] Risk factors for acute GVHD in patients receiving unrelated donor UCB have yet to be clarified. HLA match 6, 7, 17 , patient age 7 , and CMV serostatus 6 have been reported as risk factors in some studies and not others. 9, 10, 18 Therefore, we sought to identify potential risk factors in 265 consecutive recipients of UCB treated at a single institution. In this analysis, we also sought to determine the impact on the incidence of GVHD of double UCBT pioneered at the University of Minnesota as a strategy to overcome the limited number of cells available in a single unit, particularly for adults and adolescents.
Patients and Methods

Study design
Clinical and laboratory data were systematically and prospectively collected on all patients undergoing HSC transplantation and entered into the University of Minnesota Between January 1994 and June 2006, 450 patients underwent UCBT at the University of Minnesota. Because a focus of this analysis was determine the effect of double UCB transplantation on the risk of GVHD, recipients <10 years of age were ineligible (n=140), as only 7 double UCB transplants had been performed in younger patients over the time period. Other exclusion criteria were: use of a 3/6 HLA matched UCB unit (n=3) or prior allogeneic transplantation (n=42). Therefore, this analysis included 265 eligible patients aged >10 years. Eighty patients were transplanted with a single UCB unit and 185 with two UCB units. At the time of analysis, all patients had 12-110 months of follow-up (median 36 months).
Patient Characteristics
Patient characteristics, including year of transplant and recipient age, weight, gender, recipient CMV serostatus, and underlying diagnosis, are shown in Table 1 . Double UCBT was initiated in 2000; therefore, for these recipients follow up was shorter.
Patients received a double UCB graft if they lacked a suitable single UCB, as determined by cell-dose criteria. 12, 13, 19 Single UCB recipients were younger with a median age of 23 
Transplant Characteristics
Transplant characteristics including HLA match, preparative therapy, GVHD prophylaxis, and UCB graft cell dose are shown in Table 1 . Patients and donors were typed for HLA-A and -B at antigen level and for DRB1 at allele level. HLA-C, -DQ and -DP were not considered in donor unit selection. The HLA match of the single UCB unit and lowest HLA match of the two units in recipients of double UCBT were similar.
Similarly, the HLA match of the engrafting unit in recipients of two UCB units was similar to that in recipients of a single UCB unit. 8, 11 The majority (76%) of the single 
Statistical Analysis
Data on pretransplant patient characteristics, transplantation complications, and outcomes, including maximum acute GVHD score, were prospectively collected by the Biostatistical Support Group at the University of Minnesota using standardized collection procedures.
Cumulative incidence rates and their 95% confidence intervals (CIs) were estimated for engraftment, grade II-IV and grade III-IV acute GVHD, chronic GVHD, and transplantrelated mortality (TRM). Event times for neutrophil engraftment were measured from the date of transplantation to the date of neutrophil recovery, with censoring for early death (i.e., death before day 21 without neutrophil recovery; n = 4). 24 Patients who had very delayed engraftment (i.e., those who achieved an ANC ≥ 5 x 10 8 /L after day 42) were scored as having primary graft failure.
The multivariate modification of cumulative incidence statistics of Fine and Gray were used to evaluate the univariate and multiple effects of risk factors on outcome. 25 The outcome variables were engraftment, GVHD, and TRM.
Results
Acute GVHD
For the entire cohort of patients, the cumulative incidence of grade II-IV and grade III-IV acute GVHD at day 100 after UCBT was 52% (95% CI 45-59%) and 19% (95% CI 14-24%), respectively. While no factor was independently associated with the risk of grade III-IV acute GVHD, three factors were associated with the development of grade II-IV acute GVHD in multiple regression analysis, namely, transplantation of 2 UCB units, use of a non-myeloablative conditioning regimen, and absence of ATG in the conditioning regimen ( Table 2) For double UCB graft recipients, the incidence of grade II-IV acute GVHD was 58%
(95% CI 50-66%) as compared to 39% (95% CI 28-50%) in single UCB unit recipients (p<.01), as shown in Figure 1 . In addition, acute GVHD developed earlier after double
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UCBT at a median of 28 (range 11-75) days as compared to 36 (range, 14-86) days after single UCBT. In contrast, the incidence of more severe grade III-IV acute GVHD was similar between groups (i.e., 19% [95% CI 14-25%] with a double and 18% [95% CI 9-26%] with a single UCB graft). As shown in Figure 2 , recipients of two UCB units had a higher incidence of grade II disease only, manifest by a higher incidence of stage 3 skin GVHD only (44% versus 23%, p =.02). Liver and gastrointestinal acute GVHD was similar between recipients of a single and double UCB grafts. The effects of donor:recipient HLA match and GVHD prophylaxis were also examined.
None of the 7 patients who received a 6/6 HLA matched, single UCB graft developed acute GVHD as compared to 60% (95% CI, 31-89%) of 15 patients who received two 6/6 HLA matched UCB units (p = .02). HLA match of the infused single unit had no effect on risk of acute GVHD. Similarly, as shown in Figure 4 , HLA match of the engrafting unit had no direct effect on the risk of acute GVHD. However, when evaluated by single versus double UCBT, use of two units was consistently associated with a higher risk regardless of the HLA match of the engrafting unit to the recipient. While recipients of CsA and methylprednisone may have had a lower risk of acute GVHD, this association was confounded by the infusion of ATG pretransplant in all patients. In contrast, most recipients of CsA and mycophenolate mofetil (MMF) immunoprophylaxis did not receive 
Chronic GVHD
For the entire cohort of patients, the cumulative incidence of chronic GVHD after UCBT was 17% (95% CI 13-22%). The incidence was similar in recipients of a single (18% [95% CI, 9-26%]) and double (17% [95% CI, 12-23%]) UCBT (p = .47). As reported with other HSC sources, the probability of developing chronic GVHD was higher in patients with prior grade II-IV acute GVHD (26%, 95% CI 18-34%) as compared to those without (8%, [95% CI, 8-13%]; p<.01). Among those with a history of grade II-IV acute GVHD, the rates of chronic GVHD were 29% (95% CI, 5-46%) and 25% (95% CI,
7-43%) for recipients of a single versus double UCBT (p = .46).
Transplant Related Mortality (TRM)
TRM at 1 year was 39% (95% CI 28-50%) and 24% (95% CI 18-30%) after a single and double UCBT (p= .02), respectively ( Figure 5 While risk of grade III-IV acute GVHD was similar in recipients of a single and double UCBT, TRM was 43% (95% CI, 19-67%) after single as compared to 20% (95% CI, 7-33%) after a double UCB transplant (p = .06).
In multiple regression analysis, the only factor associated with TRM after grade II-IV acute GVHD was the number of infused UCB units (Table 3 
Discussion
Acute GVHD after allogeneic HSCT is often associated with increased TRM and worse survival. The purpose of this analysis was to investigate potential risk factors for acute GVHD after UCBT. Risk factors for acute GVHD after UCBT have varied between reports. While some have found associations with patient age 7 , HLA disparity 6,7 and CMV serostatus 6 , others have not. 9, 10, 18 Rates of acute GVHD in single UCBT recipients in the present analysis are similar to those reported by others. 6, 7, [26] [27] [28] However, this analysis benefits from the use of one consistent diagnostic and treatment approach for acute GVHD over time. This is the first analysis evaluating the potential impact of double UCBT on the risk of acute GVHD.
Based on this analysis, three findings emerge: acute GVHD occurs more often, and at an earlier time point after transplantation of two partially HLA matched UCB units as compared to a single unit; when acute GVHD occurs after a double UCBT, it more likely grade II in severity with involvement principally of the skin; and, TRM is significantly lower in patients with acute GVHD when transplanted with two UCB units.
A potential mechanism for the observed increase in acute GVHD after double UCBT may be the higher cell dose. While the dose of CD3+ T cells is statistically higher, the absolute difference in total numbers of CD3+ T cells is not appreciable (median 0. The focus of this analysis was on risk of acute GVHD and impact on TRM. While of considerable interest, the impact of acute GVHD on relapse risk was not evaluated with this dataset because of disease heterogeneity. A separate analysis is underway evaluating the impact of single versus double UCBT in specific diseases and by conditioning regimen.
The increased risk of acute GVHD was predominantly limited to the skin. While there was more stage 3 skin acute GVHD after double UCBT, liver and gastrointestinal tract acute GVHD was similar. Interestingly, the grade II acute GVHD associated with double UCBT in this study was associated with lower TRM. While the mechanism for this observation is unclear, it is possible that lower TRM is principally related to the higher cell dose associated with double UCBT with an effect that is independent of acute GVHD. Alternatively, double UCBT which generally results in transient dual chimerism with one unit eventually predominating 11, 13 , may somehow modulate the severity of acute GVHD and as such, lessen its clinical consequences.
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